Duearity AB

DEAR

SE0015949482

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm Other stock markets 09:30:00 25/06/2024 pm IST			5-day change	1st Jan Change
0.1352 ^SEK	-9.63%		-9.75%	-93.91%

31/05	Duearity AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
11/03	Duearity Unit Signs US Distribution Deal With Westone Laboratories	MT

Duearity AB Reports Earnings Results for the First Quarter Ended March 31, 2024

May 31, 2024 at 11:15 pm IST

Duearity AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 0.515 million. Revenue was SEK 0.517 million.

Net loss was SEK 7.2 million.

Latest news about Duearity AB

Duearity AB Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05	CI
Duearity Unit Signs US Distribution Deal With Westone Laboratories	11/03	MT
Duearity Americas Inc Enters into an Agreement with Westone Laboratories	10/03	CI
Duearity AB Reports Earnings Results for the Fourth Quarter and Eight Months Ended December 31, 2023	22/02	CI
Duearity AB Reports Sales Results for the Month of December 2023	20/12	CI
Duearity AB Reports Earnings Results for the Third Quarter and Five Months Ended September 30, 2023	30/11	CI
Duearity AB Signs Distributor Agreement - Covering Belgium, the Netherlands and Luxembourg	02/23/02	CI
Sweden's Duearity Lands Deals for Tinnitus Device in US	25/23/25	MT
Duearity Americas Inc Signs Agreements with the First Clinics in the United States	25/23/25	CI
Duearity AB Reports Earnings Results for the Second Quarter Ended June 30, 2023	24/23/24	CI
Duearity, Prime Health Distribution Enter UK Distribution Deal	27/23/27	MT
Duearity AB Enters into an Agreement with a Distributor in Great Britain	27/23/27	CI
Duearity Announces Positive Results from Duearity's User Study on People with Tinnitus	05/23/05	CI
Duearity AB Signs Distributor Agreement	23/23/23	CI
Duearity AB Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04	CI
Duearity AB Receives Market Approval in the UK	26/23/26	CI
Duearity AB Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Duearity AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23/23/23	CI
Duearity AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/22/17	CI
Duearity to Submit an Application for Approval of A Tinnitus Product in the United States	31/22/31	CI
Duearity AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/22/25	CI
Certain Shares of Duearity AB are subject to a Lock-Up Agreement Ending on 11-MAY-2022.	11/22/11	CI
Duearity AB Reports Earnings Results for the First Quarter Ended March 31, 2022	05/22/05	CI
Duearity AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	24/22/24	CI
Duearity AB Reports Earnings Results for the Full Year Ended December 31, 2021	24/22/24	CI

Duearity AB is a Sweden-based medical technology company. The Company's product is Tinearity G1. Tinearity G1 is a medical device that helps with tinnitus treatment. Tinearity G1 is based on Tinnitus Retraining Therapy, a white noise treatment that has been used clinically for several decades. Tinearity G1 consists of sound elements that lead white noise to the inner ear via the skull bone. The method is non-invasive and the ear canal is not affected.

Sector

Advanced Medical Equipment & Technology

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
DUEARITY AB	-93.91%	3L
VEEVA SYSTEMS INC.	-3.30%	3.01TCr
PRO MEDICUS LIMITED	+45.72%	991.29Cr
SECTRA AB	+36.91%	452.02Cr
EVOLENT HEALTH, INC.	-36.88%	239.1Cr
VERADIGM INC.	-8.48%	162.08Cr
OMNICELL, INC.	-29.26%	122.25Cr
SIMULATIONS PLUS, INC.	+6.61%	95Cr
LUNIT INC.	-45.05%	94Cr
B-SOFT CO.,LTD.	-46.72%	73Cr